Expertise in
3
conditions

Anneke M. Westermann

Amsterdam, NH, NL 
Expertise in
3
conditions
Amsterdam, NH, NL 
OverviewLocationsClinical Research

Overview

Anneke Westermann practices in Amsterdam, Netherlands. Ms. Westermann is highly rated in 3 conditions, according to our data. Her top areas of expertise are Cervical Cancer, Endometrial Cancer, Febrile Neutropenia, Ovarian Cancer, and Hysterectomy.

Her clinical research consists of co-authoring 48 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Amsterdam, NH, Netherlands
Other Locations
Noord, NB, Netherlands
Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin
Study Phase: Phase 1/Phase 2
A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Uterine Sarcoma (HGUtS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment
A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Uterine Sarcoma (HGUtS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment
Enrollment Status: Completed
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
View 1 Less Clinical Trial

48 Total Publications

ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025.
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025.
Journal: The Lancet. Oncology
Published: February 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Westermann's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile